InvestorsHub Logo
Followers 75
Posts 10572
Boards Moderated 0
Alias Born 07/11/2006

Re: None

Wednesday, 01/17/2007 10:16:07 AM

Wednesday, January 17, 2007 10:16:07 AM

Post# of 315345
Sandy Winick, Herbert Becker.....there IS A HISTORY maybe,

http://secure.dataovation.com/releases/2005/1/prweb199718.htm

Hutchinson, KS (PRWEB) January 21, 2005 -- The Hee Corporation, Inc. ("HEE") (HCCF on OTC Pink Sheets) today announced that its Board of Directors has unanimously voted to appoint Herbert Becker, as the Company's Interim Chief Executive Officer and Chairman of the Board, effective immediately.

Mr. Becker's appointment followed Radley Brook's move to President from his interim job as both Chief Executive Officer and President. Mr. Brook's had stepped in when Sandy Winick left the company on December 2nd, 2004.

HEE's goal is to be the premier provider of a new and extremely promising nutraceutical treatment for Type II Diabetes. HEE has acquired the worldwide distribution rights for this diabetic treatment. In the United States alone, 18.2 million people have diabetes and, unfortunately, 5.2 million (nearly one-third of that total) are not yet aware that they have it! Diabetes is the fifth leading cause of death by disease in the US. Now a modern-day epidemic, some 171,000,000 people around the globe are estimated to have diabetes (mostly Type II) and the costs of treatment and productivity losses now run into the hundreds of billions of dollars worldwide. Early indications from the Company's current phase of treatment and testing have been extremely positive, holding out great promise that an effective alternative treatment for Type II diabetes may be in sight.

"We are pleased that Herbert Becker will share his knowledge and experience as our Interim Chairman and CEO, and will lead HEE through this period of change. As a director of the advisory board, Herbert is already familiar with HEE's business and has an appreciation of our Company's strengths and its dedicated employees. His appointment provides leadership and stability, while the management team and Board work to implement a comprehensive operations improvement program that will better position the Company for growth."

Radley Brooks, a HEE director, President and member of the Board's Executive Committee, said, "Herbert comes to HEE with a wealth of operating expertise earned over the past 25 years. His experience managing change initiatives at many public and private corporations gives him immediate insight into the operational improvements we need to make at HEE. He has a solid track record of helping companies successfully take advantage of new opportunities while addressing current challenges. We firmly believe that under Herbert's leadership and the Board's continued guidance, we will accelerate our progress and be more consistent in meeting the expectations of both our shareholders and our customers."

Mr. Becker said, "I am honored that the Board has selected me to lead HEE on an interim basis, and I am excited about HEE's significant strengths and future potential. Working with the HEE team, I am committed to instilling a renewed focus on operational excellence and superior customer service throughout the Company in order to stimulate growth and deliver value to our shareholders."

"We understand the challenges that lay ahead, and we are committed to successfully addressing them. To do this, in what we all recognize is a very competitive environment, we need superb execution across our operations and to offer a compelling value proposition," continued Mr. Becker. "There's significant value embedded in HEE that can be - and will be - used for future growth and for the benefit of our customers and shareholders."

Mr. Becker has been a director of HEE's Advisory Board since 2004. He has served in various senior management and executive positions over the past 30 years.

About HEE Corporation
The HEE Corporation was founded for the purpose of marketing a new and extremely promising treatment for Type II Diabetes. HEE has acquired the worldwide distribution rights for this diabetic treatment. Just in the United States Type II Diabetes has reached epidemic levels with 18.2 million confirmed cases and an estimated 5 million cases that go undiagnosed. Hundreds of billions of dollars worldwide is spent each year on the treatment of this disease.

For more information about the Company contact us @ 620-663-3333 or visit our web site at www.hee-corp.com.

# # #

Note: Safe Harbor for Forward-Looking Statements--Except for historical information contained herein, the statements in this news release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties that may cause the company's actual results in the future to differ materially from forecasted results. These risks and uncertainties include, among other things, volatility of prices, product demand, market compensation and risk inherent in the company's international operations.

Source: The Hee Corporation, Inc.

Contact:
The Hee Corporation, Inc.
620-663-3333
www.hee-corp.com

Copyright (C) 2005 Business Wire. All rights reserved.